Processing

Please wait...

Settings

Settings

Goto Application

1. WO2021143430 - BMS-986165 HYDROCHLORIDE CRYSTAL FORM, PREPARATION METHOD THEREFOR AND USE THEREOF

Publication Number WO/2021/143430
Publication Date 22.07.2021
International Application No. PCT/CN2020/136568
International Filing Date 15.12.2020
IPC
C07D 403/12 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
403Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/167
02containing two hetero rings
12linked by a chain containing hetero atoms as chain links
A61K 31/501 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
50Pyridazines; Hydrogenated pyridazines
501not condensed and containing further heterocyclic rings
A61P 29/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
29Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (NSAIDs)
CPC
A61K 31/501
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two ; or more; nitrogen atoms as the only ring heteroatoms, e.g. piperazine ; or tetrazines
50Pyridazines; Hydrogenated pyridazines
501not condensed and containing further heterocyclic rings
A61P 29/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
29Non-central analgesic, antipyretic or anti-inflammatory agents, e.g antirheumatic agents; Non-steroidal anti-inflammatory drugs (NSAIDs)
C07D 403/12
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
403Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
02containing two hetero rings
12linked by a chain containing hetero atoms as chain links
Applicants
  • 苏州科睿思制药有限公司 CRYSTAL PHARMACEUTICAL (SUZHOU) CO., LTD. [CN]/[CN]
Inventors
  • 陈敏华 CHEN, Minhua
  • 张昊威 ZHANG, Haowei
  • 钱佳乐 QIAN, Jiale
Priority Data
202010059761.X19.01.2020CN
Publication Language Chinese (ZH)
Filing Language Chinese (ZH)
Designated States
Title
(EN) BMS-986165 HYDROCHLORIDE CRYSTAL FORM, PREPARATION METHOD THEREFOR AND USE THEREOF
(FR) FORME CRISTALLINE DE CHLORHYDRATE DE BMS-986165, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION
(ZH) 一种BMS-986165盐酸盐晶型及其制备方法和用途
Abstract
(EN)
Disclosed are a crystal of a compound I hydrochloride and a preparation method therefor, a pharmaceutical composition containing the crystal, and the use of the crystal in the preparation of a TYK2 inhibitor drug and a drug for treating psoriasis, systemic lupus erythematosus, and Crohn's disease. The crystal of the compound I hydrochloride has one or more improved properties compared with the prior art, and is of great value to the future optimization and development of the drugs.
(FR)
Est divulgué un cristal d'un chlorhydrate de composé I et son procédé de préparation, une composition pharmaceutique contenant le cristal, et l'utilisation du cristal dans la préparation d'un médicament inhibiteur de TYK2 et d'un médicament pour le traitement du psoriasis, du lupus érythémateux disséminé et de la maladie de Crohn. Le cristal de chlorhydrate du composé I a une ou plusieurs propriétés améliorées par rapport à l'état de la technique, et est de grande valeur pour l'optimisation et le développement du médicament dans le futur.
(ZH)
公开了化合物I盐酸盐的结晶及其制备方法、含有该结晶的药物组合物以及该结晶在制备TYK2 抑制剂药物和治疗银屑病、系统性红斑狼疮和克罗恩病药物中的用途。所述化合物I盐酸盐的结晶比现有技术具有一种或多种改进的性质,对未来该药物的优化和开发具有重要价值。
Latest bibliographic data on file with the International Bureau